Safety and immunogenicity of a 9-valent HPV vaccine in females 12-26 years of age who previously received the quadrivalent HPV vaccine

Suzanne M Garland, Tak-Hong Cheung, Shelly McNeill, Lone Kjeld Petersen, Josefina Romaguera, Jorge Vazquez-Narvaez, Oliver Bautista, Christine Shields, Scott Vuocolo, Alain Luxembourg

Research output: Contribution to journalJournal articleResearchpeer-review


OBJECTIVES: To assess the safety and immunogenicity of the investigational 9-valent (6/11/16/18/31/33/45/52/58) HPV (9vHPV) vaccine in prior recipients of a 3-dose regimen of quadrivalent (6/11/16/18) HPV (qHPV) vaccine.

METHODS: V503-006 was a randomized, double-blinded, safety/tolerability and immunogenicity study of the 9vHPV vaccine in females 12-26 years of age who were previously vaccinated with qHPV vaccine. Subjects were randomized in a 2:1 ratio to receive 3 doses of 9vHPV vaccine (n=618) or saline placebo (n=306) at day 1, month 2, and month 6. Systemic, injection-site and serious adverse experiences (AEs) were monitored. Serum samples were collected at day 1, month 2, and month 7. Anti-HPV 6/11/16/18/31/33/45/52/58 titers were measured using the 9-valent HPV competitive Luminex Immunoassay (cLIA).

RESULTS: The frequency of injection-site AEs (days 1-5 following any vaccination) was higher in the 9vHPV vaccine group than in the placebo group (91.1% and 43.9%, respectively). The frequencies of vaccine-related systemic AEs (days 1-15 following any vaccination) were generally comparable between the 2 groups (30.6% in the 9vHPV vaccine group, and 25.9% in the placebo group). One vaccine-related serious AE was reported in each of the 9vHPV vaccine and placebo groups. Few subjects (9vHPV=0.5%; placebo=0%) discontinued due to an AE. At 4 weeks post-dose 3, over 98% of subjects in the 9vHPV vaccine group were seropositive for HPV types 31/33/45/52/58, with marked elevations in cLIA geometric mean titers (GMTs) to these HPV types. Anti-HPV 31/33/45/52/58 GMTs were lower than in subjects administered 9vHPV vaccine who had not previously received qHPV vaccine (based on cross-study analyses); the clinical significance of this difference is unknown.

CONCLUSIONS: Administration of a 3-dose regimen of 9vHPV vaccine to adolescent girls and young women 12-26 years of age who are prior qHPV vaccine recipients is highly immunogenic with respect to HPV types 31/33/45/52/58 and generally well tolerated.

Original languageEnglish
Issue number48
Pages (from-to)6855-6864
Publication statusPublished - 27. Nov 2015
Externally publishedYes


  • Adolescent
  • Adult
  • Antibodies, Viral/blood
  • Child
  • Double-Blind Method
  • Drug-Related Side Effects and Adverse Reactions/epidemiology
  • Female
  • Humans
  • Immunoassay
  • Papillomavirus Infections/prevention & control
  • Papillomavirus Vaccines/administration & dosage
  • Placebos/administration & dosage
  • Treatment Outcome
  • Young Adult
  • Vaccine
  • HPV
  • Immunogenicity
  • 9-Valent
  • Safety


Dive into the research topics of 'Safety and immunogenicity of a 9-valent HPV vaccine in females 12-26 years of age who previously received the quadrivalent HPV vaccine'. Together they form a unique fingerprint.

Cite this